These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26833513)

  • 1. Therapeutic advances in idiopathic pulmonary fibrosis.
    Fraser E; Hoyles RK
    Clin Med (Lond); 2016 Feb; 16(1):42-51. PubMed ID: 26833513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic pulmonary fibrosis: pathogenesis and management.
    Sgalla G; Iovene B; Calvello M; Ori M; Varone F; Richeldi L
    Respir Res; 2018 Feb; 19(1):32. PubMed ID: 29471816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and Future Idiopathic Pulmonary Fibrosis Therapy.
    Richeldi L; Baldi F; Pasciuto G; Macagno F; Panico L
    Am J Med Sci; 2019 May; 357(5):370-373. PubMed ID: 31010462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiopathic pulmonary fibrosis: the turning point is now!
    Funke M; Geiser T
    Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic pulmonary fibrosis.
    Koudstaal T; Wijsenbeek MS
    Presse Med; 2023 Sep; 52(3):104166. PubMed ID: 37156412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    George PM; Wells AU
    Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances and Future Needs in Interstitial Lung Diseases.
    Jones MG; Richeldi L
    Semin Respir Crit Care Med; 2016 Jun; 37(3):477-84. PubMed ID: 27231869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
    Moodley Y; Corte T; Richeldi L; King TE
    Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis.
    Aiello M; Bertorelli G; Bocchino M; Chetta A; Fiore-Donati A; Fois A; Marinari S; Oggionni T; Polla B; Rosi E; Stanziola A; Varone F; Sanduzzi A
    Pulm Pharmacol Ther; 2017 Jun; 44():7-15. PubMed ID: 28257817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developments in the management of idiopathic pulmonary fibrosis.
    Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
    Collins BF; Raghu G
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape.
    Glassberg MK
    Am J Manag Care; 2019 Jul; 25(11 Suppl):S195-S203. PubMed ID: 31419091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
    Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
    Wongkarnjana A; Yanagihara T; Kolb MR
    Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
    [No Abstract]   [Full Text] [Related]  

  • 17. Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.
    Jo HE; Randhawa S; Corte TJ; Moodley Y
    Drugs Aging; 2016 May; 33(5):321-34. PubMed ID: 27083934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry.
    Holtze CH; Freiheit EA; Limb SL; Stauffer JL; Raimundo K; Pan WT; Flaherty KR; Kim HJ
    Respir Res; 2020 Feb; 21(1):48. PubMed ID: 32041621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.